UPDATE: CannEpil™ production has officially commenced
A word from Ron Lipsky, Manager of Business Development and International Relations at MGC Pharmaceuticals.
Thursday March 29 was a day of celebration on MGC Pharma’s timeline as we announced the commencement of production for the first batch of CannEpil™.
CannEpil™ — CBD-based treatment for people with Refractory Epilepsy — is the first product we’ve released to market. After years of testing the effects of CBD on patients with Epilepsy, we’re thrilled to finally see our hard work come to fruition, not just for the sake of progress in the Medical Cannabis industry, but also for the many people suffering from severe Epilepsy and seizures across the world.
According to the World Health Organisation (WHO), there are approximately 50 million people currently living with a form of Epilepsy throughout the world, and of those 50 million, 30% have Refractory Epilepsy. 72,000 of those are Australians.
Refractory Epilepsy is epilepsy that involves frequent and severe seizures that are difficult to treat. CBD has recently been proven to reduce the severity of seizures, which is another reason we are so excited to begin production of CannEpil™ and take a huge step towards distribution in local and international markets.
Now that we’ve achieved this milestone (following the receipt of interim GMP certification), we’re refocusing our energy on achieving full GMP certification for our European Medical Cannabis laboratory and production facility. This requires further analysis and validation (which will follow next month), where the batch will be inspected by the GMP regulatory body to ensure all protocols were followed during production. Once we do receive full GMP certification, our lab will become one of Europe’s most advanced facilities for pharmaceutical grade Medical Cannabis compounding and will also put us on track to becoming an international pioneer in Phytocannabinoid-based medicine within the biopharmaceutical industry.
The green light from the International Society for Pharmaceutical Engineering will then allow us to begin full-scale commercial production of CannEpil™, as well as developing additional pharmaceutical grade Medical Cannabis products for use in our future clinical studies, research pipelines and for public distribution.
This is an extremely exciting step forward for MGC Pharma as we seek to solve serious health issues both here in Australia and across the world, and I look forward to commencing full scale commercial production of CannEpil™ in the next few months.
You can read the full ASX announcement here.
